Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Sell
46
ARTV Quote, Financials, Valuation and Earnings
Last price:
$4.00
Seasonality move
:
-67.7%
Day range:
$3.89 - $4.14
52-week range:
$1.47 - $7.36
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
46.79x
P/B ratio:
0.76x
Volume:
40K
Avg. volume:
194.9K
1-year change:
-0.25%
Market cap:
$98.2M
Revenue:
$251K
EPS (TTM):
-$3.25
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ARTV
Artiva Biotherapeutics, Inc.
|
-- | -$0.80 | -100% | -20.74% | $17.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.62% | -58.59% | $467.62 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835.5M | $0.67 | 11.91% | 37.43% | $88.65 |
|
RCKT
Rocket Pharmaceuticals, Inc.
|
-- | -$0.44 | -- | -20.25% | $7.65 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ARTV
Artiva Biotherapeutics, Inc.
|
$4.00 | $17.00 | $98.2M | -- | $0.00 | 0% | 46.79x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.03 | $31.21 | $3.7B | 14.17x | $0.00 | 0% | 3.54x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$314.40 | $467.62 | $41.7B | 139.29x | $0.00 | 0% | 11.30x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$59.87 | $88.65 | $11.5B | 22.43x | $0.00 | 0% | 3.79x |
|
RCKT
Rocket Pharmaceuticals, Inc.
|
$3.27 | $7.65 | $353.9M | -- | $0.00 | 0% | -- |
|
SVRA
Savara, Inc.
|
$5.60 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ARTV
Artiva Biotherapeutics, Inc.
|
8.3% | 1.984 | 16.72% | 11.06x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.896 | 5.87% | 2.84x |
|
RCKT
Rocket Pharmaceuticals, Inc.
|
7.39% | -0.797 | 7.1% | 7.15x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ARTV
Artiva Biotherapeutics, Inc.
|
-$662K | -$22.9M | -43.85% | -47.44% | -5773.71% | -$19.8M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
RCKT
Rocket Pharmaceuticals, Inc.
|
-$3.2M | -$52.4M | -60.24% | -64.31% | -- | -$50.4M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
Artiva Biotherapeutics, Inc. vs. Competitors
-
Which has Higher Returns ARTV or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -5562.95% compared to Artiva Biotherapeutics, Inc.'s net margin of 25.76%. Artiva Biotherapeutics, Inc.'s return on equity of -47.44% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital ARTVArtiva Biotherapeutics, Inc.-- -$0.88 $140.9M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About ARTV or ACAD?
Artiva Biotherapeutics, Inc. has a consensus price target of $17.00, signalling upside risk potential of 325%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 41.67%. Given that Artiva Biotherapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Artiva Biotherapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARTVArtiva Biotherapeutics, Inc.5 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is ARTV or ACAD More Risky?
Artiva Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock ARTV or ACAD?
Artiva Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Artiva Biotherapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARTV or ACAD?
Artiva Biotherapeutics, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Artiva Biotherapeutics, Inc.'s net income of -$21.5M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Artiva Biotherapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 14.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Artiva Biotherapeutics, Inc. is 46.79x versus 3.54x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARTVArtiva Biotherapeutics, Inc.46.79x -- -- -$21.5M ACADACADIA Pharmaceuticals, Inc.3.54x 14.17x $278.6M $71.8M
-
Which has Higher Returns ARTV or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -5562.95% compared to Artiva Biotherapeutics, Inc.'s net margin of 16.99%. Artiva Biotherapeutics, Inc.'s return on equity of -47.44% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital ARTVArtiva Biotherapeutics, Inc.-- -$0.88 $140.9M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About ARTV or ALNY?
Artiva Biotherapeutics, Inc. has a consensus price target of $17.00, signalling upside risk potential of 325%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $467.62 which suggests that it could grow by 48.74%. Given that Artiva Biotherapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Artiva Biotherapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARTVArtiva Biotherapeutics, Inc.5 0 0 ALNYAlnylam Pharmaceuticals, Inc.14 8 0 -
Is ARTV or ALNY More Risky?
Artiva Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock ARTV or ALNY?
Artiva Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Artiva Biotherapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARTV or ALNY?
Artiva Biotherapeutics, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Artiva Biotherapeutics, Inc.'s net income of -$21.5M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Artiva Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 139.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Artiva Biotherapeutics, Inc. is 46.79x versus 11.30x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARTVArtiva Biotherapeutics, Inc.46.79x -- -- -$21.5M ALNYAlnylam Pharmaceuticals, Inc.11.30x 139.29x $1.1B $186.4M
-
Which has Higher Returns ARTV or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -5562.95% compared to Artiva Biotherapeutics, Inc.'s net margin of -3.91%. Artiva Biotherapeutics, Inc.'s return on equity of -47.44% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital ARTVArtiva Biotherapeutics, Inc.-- -$0.88 $140.9M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About ARTV or BMRN?
Artiva Biotherapeutics, Inc. has a consensus price target of $17.00, signalling upside risk potential of 325%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.65 which suggests that it could grow by 48.07%. Given that Artiva Biotherapeutics, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Artiva Biotherapeutics, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARTVArtiva Biotherapeutics, Inc.5 0 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is ARTV or BMRN More Risky?
Artiva Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock ARTV or BMRN?
Artiva Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Artiva Biotherapeutics, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARTV or BMRN?
Artiva Biotherapeutics, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Artiva Biotherapeutics, Inc.'s net income of -$21.5M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Artiva Biotherapeutics, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 22.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Artiva Biotherapeutics, Inc. is 46.79x versus 3.79x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARTVArtiva Biotherapeutics, Inc.46.79x -- -- -$21.5M BMRNBioMarin Pharmaceutical, Inc.3.79x 22.43x $786.8M -$30.7M
-
Which has Higher Returns ARTV or RCKT?
Rocket Pharmaceuticals, Inc. has a net margin of -5562.95% compared to Artiva Biotherapeutics, Inc.'s net margin of --. Artiva Biotherapeutics, Inc.'s return on equity of -47.44% beat Rocket Pharmaceuticals, Inc.'s return on equity of -64.31%.
Company Gross Margin Earnings Per Share Invested Capital ARTVArtiva Biotherapeutics, Inc.-- -$0.88 $140.9M RCKTRocket Pharmaceuticals, Inc.-- -$0.45 $338.7M -
What do Analysts Say About ARTV or RCKT?
Artiva Biotherapeutics, Inc. has a consensus price target of $17.00, signalling upside risk potential of 325%. On the other hand Rocket Pharmaceuticals, Inc. has an analysts' consensus of $7.65 which suggests that it could grow by 133.95%. Given that Artiva Biotherapeutics, Inc. has higher upside potential than Rocket Pharmaceuticals, Inc., analysts believe Artiva Biotherapeutics, Inc. is more attractive than Rocket Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARTVArtiva Biotherapeutics, Inc.5 0 0 RCKTRocket Pharmaceuticals, Inc.6 6 1 -
Is ARTV or RCKT More Risky?
Artiva Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Rocket Pharmaceuticals, Inc. has a beta of 0.480, suggesting its less volatile than the S&P 500 by 51.982%.
-
Which is a Better Dividend Stock ARTV or RCKT?
Artiva Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rocket Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Artiva Biotherapeutics, Inc. pays -- of its earnings as a dividend. Rocket Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARTV or RCKT?
Artiva Biotherapeutics, Inc. quarterly revenues are --, which are smaller than Rocket Pharmaceuticals, Inc. quarterly revenues of --. Artiva Biotherapeutics, Inc.'s net income of -$21.5M is higher than Rocket Pharmaceuticals, Inc.'s net income of -$50.3M. Notably, Artiva Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Rocket Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Artiva Biotherapeutics, Inc. is 46.79x versus -- for Rocket Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARTVArtiva Biotherapeutics, Inc.46.79x -- -- -$21.5M RCKTRocket Pharmaceuticals, Inc.-- -- -- -$50.3M
-
Which has Higher Returns ARTV or SVRA?
Savara, Inc. has a net margin of -5562.95% compared to Artiva Biotherapeutics, Inc.'s net margin of --. Artiva Biotherapeutics, Inc.'s return on equity of -47.44% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital ARTVArtiva Biotherapeutics, Inc.-- -$0.88 $140.9M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About ARTV or SVRA?
Artiva Biotherapeutics, Inc. has a consensus price target of $17.00, signalling upside risk potential of 325%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 93.08%. Given that Artiva Biotherapeutics, Inc. has higher upside potential than Savara, Inc., analysts believe Artiva Biotherapeutics, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARTVArtiva Biotherapeutics, Inc.5 0 0 SVRASavara, Inc.6 0 0 -
Is ARTV or SVRA More Risky?
Artiva Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock ARTV or SVRA?
Artiva Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Artiva Biotherapeutics, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARTV or SVRA?
Artiva Biotherapeutics, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Artiva Biotherapeutics, Inc.'s net income of -$21.5M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Artiva Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Artiva Biotherapeutics, Inc. is 46.79x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARTVArtiva Biotherapeutics, Inc.46.79x -- -- -$21.5M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Is Sandisk The Next Big Memory Stock?
Computer memory manufacturer Sandisk (NASDAQ:SNDK) has quietly been one of…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
58
TPH alert for Feb 14
Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.
Sell
20
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
